Magnesium Sulphate and Extubation Quality

The Effect of Magnesium Sulfate on Extubation Quality Score and Recovery in Larynx Laser Microsurgery, Prospective, Randomized, Controlled Study

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT05858957

Enrollment

Registered

2023-05-15

Start date

2023-04-20

Completion date

2023-07-30

Last updated

2024-01-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Perioperative Complication

Brief summary

The investigators aimed to search effect of magnesium Sulfate on extubation quality scores, recovery and pain in larynx micro surgery. The patients allocated to two groups to receive magnesium sulfate 30 mg/kg in 100 ml saline infusion (maximum 2g) (Group m) or saline 100 ml (Group S) before induction of anesthesia. Anesthesia induction performed with propofol 2 mg/kg, rocuronium 0.6 mg/kg, remifentanil 0.5 µg/kg and general anesthesia maintained with total intravenous anesthesia (propofol 3-7 mg/kg, remifentanil 0.05-0.1 µg/kg/min and O2/air 30/70 mixture) to the all patients. Extubation quality scores, Extubation time, NRS scores were assessed.

Detailed description

The investigators aimed to search effect of magnesium sulfate on extubation quality, recovery feature and complications.98 adult patients scheduled for larynx laser microsurgery were included and randomly allocated to two groups to receive magnesium sulfate 30 mg/kg in 100 ml saline infusion (maximum 2g) (Group m) or saline 100 ml (Group S) before induction of anesthesia. Anesthesia induction performed with propofol 2 mg/kg, rocuronium 0.6 mg/kg, remifentanil 0.5 µg/kg and general anesthesia maintained with total intravenous anesthesia (propofol 3-7 mg/kg, remifentanil 0.05-0.1 µg/kg/min and O2/air 30/70 mixture) to the all patients. Paracetamol 15 mg/kg applied to all patients.Extubation quality score, extubation time, stay in postanesthesia unit (PACU) time, numeric rating scale (NRS) and complications were recorded.

Interventions

DRUGMagnesium sulfate

magnesium sulphate IV 30 mg/kg (10 min) infusion apply to the Group M

DRUGSaline

100 ml saline infusion apply to the Group S

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Masking

SINGLE (Subject)

Eligibility

Sex/Gender

ALL

Age

18 Years to 90 Years

Healthy volunteers

Inclusion criteria

* 18 age over * American society of Anesthesiology (ASA) clinical status I-III * the patients who experience larynx micro surgery

Exclusion criteria

* under 18 years old * ASA IV and over * severe airway obstruction * neuromuscular disease * presence of tracheostomy

Design outcomes

Primary

Measure	Time frame	Description
extubation quality scores	at the time between stop the total intravenous anesthesia and extubation of patient (last 20 min of anesthesia).	Extubation quality will assess with quality scores such as no cough, Mild cough, moderate cough, severe cough.

Secondary

Measure	Time frame	Description
extubation time	time between stop the total intravenous anesthesia and extubation of patient (last 20 min of anesthesia).	The time need to adequate spontaneous ventilation at recovery period

Countries

Turkey (Türkiye)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026